The Trump administration proposed ending a complex system of drug rebates that influence tens of billions of dollars in U.
S. pharmaceutical spending,a journey that could upend the relationship between drugmakers and pharmacy benefits middlemen. The proposal, a long-awaited part …
Source: insurancejournal.com